Receptor for AGEs (RAGE) as mediator of NF-kB pathway activation in neuroinflammation and oxidative stress

CNS and Neurological Disorders - Drug Targets

Volumn 13, Issue 9, 2014, Pages 1615-1626

  Tobón Velasco, Julio C ^a   Cuevas, Elvis ^b   Torres Ramos, MóNica A ^c  

^a HOSPITAL GENERAL DE MÉXICO   (Mexico)

^b NATIONAL CENTER FOR TOXICOLOGICAL RESEARCH   (United States)

^c NATIONAL INSTITUTE OF NEUROLOGY AND NEUROSURGERY   (Mexico)

Author keywords

Neurodegeneration; Neuroinflammation; NF kB pathway; Oxidative stress; RAGE signaling

Indexed keywords

ADVANCED GLYCATION END PRODUCT RECEPTOR; ADVANCED GLYCATION END PRODUCT RECEPTOR ANTAGONIST; AMYLOID BETA PROTEIN; CD11B ANTIGEN; HIGH MOBILITY GROUP B1 PROTEIN; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; ISOPROTEIN; JANUS KINASE; MESSENGER RNA; MITOGEN ACTIVATED PROTEIN KINASE; PHOSPHATIDYLINOSITOL 3 KINASE; PHOSPHATIDYLSERINE; PREALBUMIN; PROTEIN CDC42; PROTEIN S100B; RAC PROTEIN; RAS PROTEIN; REACTIVE OXYGEN METABOLITE; STAT PROTEIN; STRESS ACTIVATED PROTEIN KINASE;

ALZHEIMER DISEASE; AMYOTROPHIC LATERAL SCLEROSIS; ARTICLE; GENE; GLYCOSYLATION; HUMAN; HUNTINGTON CHOREA; INTRACELLULAR SIGNALING; LIGAND BINDING; MEDIATOR; MICROGLIA; NERVOUS SYSTEM INFLAMMATION; NONHUMAN; OXIDATIVE STRESS; PARKINSON DISEASE; SIGNAL TRANSDUCTION;

EID: 84920609361     PISSN: 18715273     EISSN: 19963181     Source Type: Journal    
DOI: 10.2174/1871527313666140806144831     Document Type: Article

References (108)

1. Neeper M, Schmidt AM, Brett J, et al. Cloning and expression of a cell surface receptor for advanced glycosylation end products of proteins. J Biol Chem 1992; 267(21): 14998-5004.
2. Kislinger T, Fu C, Huber B, et al. N(epsilon)-(carboxymethyl) lysine adducts of proteins are ligands for receptor for advanced glycation end products that activate cell signaling pathways and modulate gene expression. J Biol Chem 1999; 274: 31740-9.
3. Deane R, Du Yan S, Submamaryan RK, et al. RAGE mediates amyloid-beta peptide transport across the blood-brain barrier and accumulation in brain. Nat Med 2003; 9: 907-13.
4. Villarreal A, Aviles Reyes RX, Angelo MF, Reines AG, Ramos AJ. S100B alters neuronal survival and dendrite extension via RAGE-mediated NF-κB signaling. J Neurochem 2011; 117(2): 321-32.
5. Hofmann MA, Drury S, Fu C, et al. RAGE mediates a novel proinflammatory axis: a central cell surface receptor for S100/calgranulin polypeptides. Cell 1999; 97: 889-901.
6. Schmidt AM, Stern DM. Receptor for age (RAGE) is a gene within the major histocompatibility class III region: implications for host response mechanisms in homeostasis and chronic disease. Front Biosci 2001; 6: D1151-60.
7. Schmidt AM, Vianna M, Gerlach M, et al. Isolation and characterization of two binding proteins for advanced glycosylation end products from bovine lung which are present on the endothelial cell surface. J Biol Chem 1992; 267: 14987-97.
8. Bierhaus A, Humpert PM, Morcos M, et al. Understanding RAGE, the receptor for advanced glycation end products. J Mol Med 2005; 83(11): 876-86.
9. Hudson BI, Carter AM, Harja E, et al. Identification, classification, and expression of RAGE gene splice variants. FASEB J 2008; 22: 1572-80.
10. Schlueter C, Hauke S, Flohr AM, Rogalla P, Bullerdiek J. Tissue specific expression patterns of the RAGE receptor and its soluble form-a result of regulated alternative splicing? Biochem Biophys Acta 2003; 1639; 1-6.
11. Koch M, Chitayat S, Dattilo BM, et al. Structural basis for ligand recognition and activation of RAGE. Structure 2010; 18: 1342-52.
12. Kalea AZ, Schmidt AM, Hudson BI. Alternative splicing of RAGE: roles in biology and disease. Front Biosci 2011; 16: 2756- 70.
13. Thornalley PJ. Cell activation by glycated proteins. AGE receptors, receptor recognition factors and functional classification of AGEs. Cell Mol Biol 1998; 44: 1013-23.
14. Raucci A, Cugusi S, Antonelli A, et al. A soluble form of the receptor for advanced glycation end products (RAGE) is produced by proteolytic cleavage of the membrane-bound form by the sheddase a disintegrin and metalloprotease 10 (ADAM10). FASEB J 2008; 22: 3716-27.
15. Zeng S, Feirt N, Goldstein M, et al. Blockade of receptor for advanced glycation end product (RAGE) attenuates ischemia and reperfusion injury to the liver in mice. Hepatology 2004; 39: 422- 32.
16. Medzhitov R, Janeway CA Jr. Innate immunity: the virtues of a nonclonal system of recognition. Cell 1997; 91(3): 295-8.
17. Taylor ME, Drickamer K. Structural requirements for high affinity binding of complex ligands by the macrophage mannose receptor. J Biol Chem 1993; 268(1): 399-404.
18. Rouhiainen A, Kuja-Panula J, Tumova S, Rauvala H. RAGEmediated cell signaling. Methods Mol Biol 2013; 963: 239-63.
19. Ostendorp T, Leclerc E, Galichet A, et al. Structural and functional insights into RAGE activation by multimeric S100B. EMBO J 2007; 26: 3868-78.
20. Alexiou P, Chatzopoulou M, Pegklidou K, Demopoulos VJ. RAGE: a multi-ligand receptor unveiling novel insights in health and disease. Curr Med Chem 2010; 17(21): 2232-52.
21. Hofmann Bowman MA, Schmidt AM. S100/calgranulins ENRAGEing the blood vessels: implications for inflammatory responses and atherosclerosis. Am J Cardiovasc Dis 2011; 1(1): 92- 100.
22. Taguchi A, Blood DC, del Toro G, et al. Blockade of RAGEamphoterin signaling suppresses tumour growth and metastases. Nature 2000; 405: 354-60.
23. Webster SJ, Mruthinti S, Hill WD, Buccafusco JJ, Terry AV Jr. An aqueous orally active vaccine targeted against a RAGE/AB complex as a novel therapeutic for Alzheimer's disease. Neuromol Med 2012; 14(2): 119-30.
24. Rasheed Z, Akhtar N, Haqqi TM. Advanced glycation end products induce the expression of interleukin-6 and interleukin-8 by receptor for advanced glycation end product-mediated activation of mitogen-activated protein kinases and nuclear factor-κB in human osteoarthritis chondrocytes. Rheumatology 2011; 50(5): 838-51.
25. Dattilo BM, Fritz G, Leclerc E, et al. The extracellular region of the receptor for advanced glycation end products is composed of two independent structural units. Biochemistry 2007; 46: 6957-70.
26. Chavakis T, Bierhaus A, Al-Fakhri N, et al. The pattern recognition receptor (RAGE) is a counterreceptor for leukocyte integrins: a novel pathway for inflammatory cell recruitment. J Exp Med 2003; 198: 1507-15.
27. Hreggvidsdóttir HS, Lundberg AM, Aveberger AC, et al. High mobility group box protein 1 (HMGB1)-partner molecule complexes enhance cytokine production by signaling through the partner molecule receptor. Mol Med 2012; 18: 224-30.
28. Baynes JW, Thorpe SR. Role of oxidative stress in diabetic complications: a new perspective on an old paradigm. Diabetes 1999; 48: 1-9.
29. Raposeiras-Roubin S, Rodiño-Janeiro BK, Grigorian-Shamagian L, et al. Soluble receptor of advanced glycation end products levels are related to ischaemic aetiology and extent of coronary disease in chronic heart failure patients, independent of advanced glycation end products levels: New Roles for Soluble RAGE. Eur J Heart Fail 2010; 12: 1092-100.
30. Basta G, Lazzerini G, Massaro M, et al. Advanced glycation end products activate endothelium through signal-transduction receptor RAGE: a mechanism for amplification of inflammatory responses. Circulation 2002; 105: 816-22.
31. Basta G, Schmidt AM, De Caterina R. Advanced glycation end products and vascular inflammation: implications for accelerated atherosclerosis in diabetes. Cardiovasc Res 2004; 63: 582-92.
32. Xie J, Reverdatto S, Frolov A, et al. Structural basis for pattern recognition by the receptor for advanced glycation end products (RAGE). J Biol Chem 2008; 283: 27255-69.
33. Liliensiek B, Weigand MA, Bierhaus A, et al. Receptor for advanced glycation end products (RAGE) regulates sepsis but not the adaptive immune response. J Clin Invest 2004; 113(11): 1641- 50.
34. Akirav EM, Preston-Hurlburt P, Garyu J, et al. RAGE expression in human T cells: a link between environmental factors and adaptive immune responses. PLoS One 2012; 7(4): e34698.
35. Arancio O, Zhang HP, Chen X, et al. RAGE potentiates Abetainduced perturbation of neuronal function in transgenic mice. EMBO J 2004; 23: 4096-105.
36. Bakris GL, Bank AJ, Kass DA, et al. Advanced glycation endproduct cross-link breakers. A novel approach to cardiovascular pathologies related to the aging process. Am J Hypertens 2004; 17: 23S-30S.
37. Lue LF, Walker DG, Brachova L, et al. Involvement of microglial receptor for advanced glycation end products (RAGE) in Alzheimer’s disease: identification of a cellular activation mechanism. Exp Neurol 2001; 171: 29-45.
38. Makita Z, Radoff S, Rayfield EJ, et al. Advanced glycosylation end products in patients with diabetic nephropathy. N Engl J Med 1991; 325(12): 836-42.
39. Fujisawa K, Katakami N, Kaneto H, et al. Circulating soluble RAGE as a predictive biomarker of cardiovascular event risk in patients with type 2 diabetes. Atherosclerosis 2013; 227(2): 425-8.
40. Lander HM, Taurus JM, Ogiste JS, et al. Activation of the receptor for advanced glycation end products triggers a p21(ras)-dependent mitogen-activated protein kinase pathway regulated by oxidant stress. J Biol Chem 1997; 272: 17810-4.
41. Lu C, He JC, Cai W, et al. Advanced glycation endproduct (AGE) receptor 1 is a negative regulator of the inflammatory response to AGE in mesangial cells. Proc Natl Acad Sci USA 2004; 101(32): 11767-72.
42. Kang R, Tang D, Lotze MT, Zeh HJ 3rd. RAGE regulates autophagy and apoptosis following oxidative injury. Autophagy 2011; 7(4): 442-4.
43. Marsche G, Weigle B, Sattler W, Malle E. Soluble RAGE blocks scavenger receptor CD36-mediated uptake of hypochloritemodified low-density lipoprotein. FASEB J 2007; 21(12): 3075-82.
44. Wei Q, Ren X, Jiang Y, et al. Advanced glycation end products accelerate rat vascular calcification through RAGE/oxidative stress. BMC Cardiovasc Disord 2013; 13: 13.
45. Park S, Yoon SJ, Tae HJ, Shim CY. RAGE and cardiovascular disease. Front Biosci 2011; 16: 486-97.
46. Yan SD, Chen X, Fu J, et al. RAGE and amyloid β peptide neurotoxicity in Alzheimer’s disease. Nature 1996; 382: 685-91.
47. Guglielmotto M, Aragno M, Tamagno E, et al. AGEs/RAGE complex upregulates BACE1 via NF-κB pathway activation. Neurobiol Aging 2012; 33(1): 19613-27.
48. Bucciarelli LG, Wendt T, Rong L, et al. RAGE is a multiligand receptor of the immunoglobulin superfamily: implications for homeostasis and chronic disease. Cell Mol Life Sci 2002; 59: 1117- 28.
49. Li J, Schmidt AM. Characterization and functional analysis of the promoter of RAGE, the receptor for advanced glycation end products. J Biol Chem 1997; 272: 16498-506.
50. Huang JS, Guh JY, Chen HC, et al. Role of receptor for advanced glycation end-product (RAGE) and the JAK/STAT-signaling pathway in AGE-induced collagen production in NRK-49F cells. J Cell Biochem 2001; 81: 102-13.
51. Wautier MP, Chappey O, Corda S, et al. Activation of NADPH oxidase by AGE links oxidant stress to altered gene expression via RAGE. Am J Physiol Endocrinol Metab 2001; 280: E685-94.
52. Soman S, Raju R, Sandhya VK, et al. A multicellular signal transduction network of AGE/RAGE signaling. J Cell Commun Signal 2013; 7(1): 19-23.
53. Takuma K, Fang F, Zhang W, et al. RAGE-mediated signaling contributes to intraneuronal transport of amyloid-beta and neuronal dysfunction. Proc Natl Acad Sci USA 2009; 106: 20021-6.
54. Huttunen HJ, Fages C, Rauvala H. Receptor for advanced glycation end products (RAGE)-mediated neurite outgrowth and activation of NF-kappaB require the cytoplasmic domain of the receptor but different downstream signaling pathways. J Biol Chem 1999; 274: 19919-24.
55. Bianchi R, Kastrisianaki E, Giambanco I, Donato R. S100B protein stimulates microglia migration via RAGE-dependent upregulation of chemokine expression and release. J Biol Chem 2011; 286(9): 7214-26.
56. Rai V, Maldonado AY, Burz DS, et al. Signal transduction in receptor for advanced glycation end products (RAGE): solution structure of C-terminal rage (ctRAGE) and its binding to mDia1. J Biol Chem 2012; 287(7): 5133-44.
57. Kierdorf K, Fritz G. RAGE regulation and signaling in inflammation and beyond. J Leukoc Biol, 2013; 94(1): 55-68.
58. Pearson MA, O'Farrellm AM, Dexterm TM, et al. Investigation of the molecular mechanisms underlying growth factor synergy: the role of ERK 2 activation in synergy. Growth Factors 1998; 15(4): 293-306.
59. Li G, Xu J, Li Z. Receptor for advanced glycation end products inhibits proliferation in osteoblast through suppression of Wnt, PI3K and ERK signaling. Biochem Biophys Res Commun 2012; 423(4): 684-9.
60. Bierhaus A, Stern DM, Nawroth PP. RAGE in inflammation: a new therapeutic target? Curr Opin Investig Drugs 2006; 7, 985-91.
61. Robinson AB, Johnson KD, Bennion BG, Reynolds PR. RAGE signaling by alveolar macrophages influences tobacco smokeinduced inflammation. Am J Physiol Lung Cell Mol Physiol 2012; 302(11): L1192-9.
62. Clynes R, Moser B, Yan SF, et al. Receptor for AGE (RAGE): weaving tangled webs within the inflammatory response. Curr Mol Med 2007; 7: 743-51.
63. Chen Y, Akirav EM, Chen W, et al. RAGE ligation affects T cell activation and controls T cell differentiation. J Immunol 2008; 181: 4272-8.
64. Shaikh SB, Uy B, Perera A, Nicholson LF. AGEs-RAGE mediated up-regulation of connexin43 in activated human microglial CHME- 5 cells. Neurochem Int 2012; 60(6): 640-51.
65. Volz HC, Laohachewin D, Seidel C, et al. S100A8/A9 aggravates post-ischemic heart failure through activation of RAGE-dependent NF-κB signaling. Basic Res Cardiol 2012; 107(2): 250.
66. Bierhaus A, Schiekofer S, Schwaninger M, et al. Diabetesassociated sustained activation of the transcription factor nuclear factor-kappaB. Diabetes 2001; 50: 2792-808.
67. Coughlan MT, Thorburn DR, Penfold SA, Laskowski A, Harcourt BE, Sourris KC, Tan AL, Fukami K, Thallas-Bonke V, Nawroth PP, Brownlee M, Bierhaus A, Cooper ME, Forbes JM. RAGEinduced cytosolic ROS promote mitochondrial superoxide generation in diabetes. J Am Soc Nephrol 2009; 20(4): 742-52.
68. Ukeda H, Hasegawa Y, Ishi T, Sawamura M. Inactivation of Cu,Zn-superoxide dismutase by intermediates of Maillard reaction and glycolytic pathway and some sugars. Biosci Biotechnol Biochem 1997; 61: 2039-42.
69. Yim MB, Yim HS, Lee C, Kang SO, Chock PB. Protein glycation: creation of catalytic sites for free radical generation. Ann NY Acad Sci 2001; 928: 48-53.
70. Lee C, Yim MB, Chock PB, Yim HS, Kang SO. Oxidationreduction properties of methylglyoxal-modified protein in relation to free radical generation. J Biol Chem 1998; 273: 25272-8.
71. Kang R, Tang D, Lotze MT, Zeh HJ 3rd. RAGE regulates autophagy and apoptosis following oxidative injury. Autophagy 2011; 7(4): 442-4.
72. DeVerse JS, Bailey KA, Jackson KN, Passerini AG. Shear stress modulates RAGE-mediated inflammation in a model of diabetesinduced metabolic stress. Am J Physiol Heart Circ Physiol 2012; 302(12): H2498-508.
73. Chen Y, Yan SS, Colgan J, et al. Blockade of Late Stages of Autoimmune Diabetes by Inhibition of the Receptor for Advanced Glycation End Products. J Immunol 2004; 173: 1399-405.
74. Byun K, Bayarsaikhan E, Kim D, et al. Induction of neuronal death by microglial AGE-albumin: implications for Alzheimer's disease. PLoS One 2012; 7(5): e37917.
75. Block ML, Zecca L, Hong JS. Microglia-mediated neurotoxicity: uncovering the molecular mechanisms. Nat Rev Neurosci 2007; 8(1): 57-69.
76. Johnson LV, Leitner WP, Rivest AJ, et al. The Alzheimer's A β - peptide is deposited at sites of complement activation in pathologic deposits associated with aging and age-related macular degeneration. Proc Natl Acad Sci USA 2002; 18: 11830-5.
77. Sinha M, Behera P, Bhowmick P, et al. Aging promotes amyloid-β peptide induced mitochondrial dysfunctions in rat brain: a molecular link between aging and Alzheimer's disease. J Alzheimers Dis 2011; 27(4): 753-65.
78. Du H, Li P, Wang J, Qing X, Li W. The interaction of amyloid β and the receptor for advanced glycation endproducts induces matrix metalloproteinase-2 expression in brain endothelial cells. Cell Mol Neurobiol 2012; 32(1): 141-7.
79. Hadding A, Kaltschmidt B, Kaltschmidt C. Overexpression of receptor of advanced glycation end products hypersensitizes cells for amyloid beta peptide-induced cell death. Biochim Biophys Acta 2004; 1691; 67-72.
80. Cuevas E, Lantz SM, Tobón-Velasco JC, et al. On the in vivo early toxic properties of A-beta 25-35 peptide in the rat hippocampus: involvement of the Receptor-for-Advanced Glycation End- Products and changes in gene expression. Neurotoxicol Teratol 2011; 33(2): 288-96.
81. Emanuele E, D’Angelo A, Tomaino C, et al. Circulating levels of soluble receptor for advanced glycation end products in Alzheimer disease and vascular dementia. Arch Neurol 2005; 62: 1734-6.
82. Vitek MP, Bhattacharya K, Glendening JM, et al. Advanced glycation end products contribute to amyloidosis in Alzheimer disease. Proc Natl Acad Sci USA 1994; 91: 4766-70.
83. Chen K, Maley J, Yu PH. Potential inplications of endogenous aldehydes in β -amyloid misfolding, oligomerization and fibrillogenesis. J Neurochem 2006; 99: 1413-24.
84. Kuhla B, Boeck K, Schmidt A, et al. Age- and stage-dependent glyoxalase I expression and its activity in normal and Alzheimer’s disease brains. Neurobiol Aging 2007; 28: 29-41.
85. Li XH, Lv BL, Xie JZ, et al. AGEs induce Alzheimer-like tau pathology and memory deficit via RAGE-mediated GSK-3 activation. Neurobiol Aging 2012; 33(7): 1400-10.
86. Sasaki N, Toki S, Chowei H, et al. Immunohistochemical distribution of the receptor for advanced glycation end products in neurons and astrocytes in Alzheimer’s disease. Brain Res 2001; 888: 256-62.
87. Tobón-Velasco JC, Carmona-Aparicio L, Ali SF, Santamaría A. Biomarkers of cell damage induced by oxidative stress in Parkinson's disease and related models. Cent Nerv Syst Agents Med Chem 2010; 10(4): 278-86.
88. Pérez-De la Cruz V, Carrillo-Mora P, Santamaría A. Huntington's disease and mitochondrial alterations: emphasis on experimental models. J Bioenerg Biomembr 2010; 42(3): 207-15.
89. Castellani R, Smith MA, Richey PL, Perry G. Glycoxidation and oxidative stress in Parkinson disease and diffuse Lewy body disease. Brain Res 1996; 737: 195-200.
90. Ma L, Nicholson LF. Expression of the receptor for advanced glycation end products in Huntington’s disease caudate nucleus. Brain Res 2004; 1018; 10-7.
91. Lee D, Park CW, Paik SR, Choi KY. The modification of α - synuclein by dicarbonyl compounds inhibits its fibril-forming process. Biochim Biophys Acta 2009; 1794; 421-30.
92. Cuevas E, Lantz S, Newport G, et al. On the early toxic effect of quinolinic acid: involvement of RAGE. Neurosci Lett 2010; 474(2): 74-8.
93. Anzilotti S, Giampà C, Laurenti D, et al. Immunohistochemical localization of receptor for advanced glycation end (RAGE) products in the R6/2 mouse model of Huntington's disease. Brain Res Bull 2012; 87(2-3): 350-8.
94. Kikuchi S, Shinpo K, Takeuchi M, et al. Glycation—a sweet tempter for neuronal death. Brain Res Rev 2003; 41: 306-23.
95. Vicente-Miranda H, Outeiro TF. The sour side of neurodegenerative disorders: the effects of protein glycation. J Pathol 2010; 221(1): 13-25.
96. Iłzecka J. Serum-soluble receptor for advanced glycation end product levels in patients with amyotrophic lateral sclerosis. Acta Neurol Scand 2009; 120(2): 119-22.
97. Qin J, Goswami R, Dawson S, Dawson G. Expression of the receptor for advanced glycation end products in oligodendrocytes in response to oxidative stress. J Neurosci Res 2008; 86(11): 2414- 22.
98. Sousa MM, Saraiva MJ. Neurodegeneration in familial amyloid polyneuropathy: from pathology to molecular signaling. Prog Neurobiol 2003; 71(5): 385-400.
99. Elosta A, Ghous T, Ahmed N. Natural products as anti-glycation agents: possible therapeutic potential for diabetic complications. Curr Diabetes Rev 2012; 8: 92-108.
100. Vasan S, Foiles P, Founds H. Therapeutic potential of breakers of advanced glycation end product-protein crosslinks. Arch Biochem Biophys 2003; 419: 89-96.
101. Van Schaftingen E, Collard F, Wiame E, Veiga-da-Cunha M. Enzymatic repair of Amadori products. Amino Acids 2012; 42: 1143-50.
102. Xue M, Rabbani N, Thornalley PJ. Glyoxalase in ageing. Semin Cell Dev Biol 2011; 22: 293-301.
103. Kim KM, Kim YS, Jung DH, Lee J, Kim JS. Increased glyoxalase I levels inhibit accumulation of oxidative stress and an advanced glycation end product in mouse mesangial cells cultured in high glucose. Exp Cell Res 2012; 318: 152-9.
104. Xue M, Rabbani N, Momiji H, et al. Transcriptional control of glyoxalase 1 by Nrf2 provides a stress-responsive defence against dicarbonyl glycation. Biochem J 2012; 443: 213-22.
105. Hudson BI, Bucciarelli LG, Wendt T, et al. Blockade of receptor for advanced glycation endproducts: a new target for therapeutic intervention in diabetic complications and inflammatory disorders. Arch Biochem Biophys 2003; 419: 80-8.
106. Ramasamy R, Vannucci SJ, Yan SS, et al. Advanced glycation end products and RAGE: a common thread in aging, diabetes, neurodegeneration, and inflammation. Glycobiology 2005; 15: 16R-28R.
107. Goova MT, Li J, Kislinger T, et al. Blockade of receptor for advanced glycation end-products restores effective wound healing in diabetic mice. Am J Pathol 2001; 159: 513-25.
108. Reddy VP, Beyaz A. Inhibitors of the Maillard reaction and AGE breakers as therapeutics for multiple diseases. Drug Discov Today 2006; 11(13-14): 646-54.